Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

UCB and Wilex enter to develop preclinical oncology portfolio
February 2009
SHARING OPTIONS:

BRUSSELS, BelgiumUCB Pharma S.A. and Munich, Germany-based Wilex AG recently forged a strategic partnership, whereby Wilex will acquire worldwide rights to develop UCB's entire preclinical oncology portfolio, comprising two small-molecule programs and three antibody programs. Under the partnership, UCB retains exclusive rights to re-purchase each of the five programs, following completion of initial clinical feasibility studies for each program, and assume the responsibility for further development and commercialization of each product. In this case, Wilex will receive development and commercialization milestone payments and royalty payments from UCB. Alternatively, in the event UCB does not exercise its re-purchase right for each program, Wilex will retain rights to develop as well as commercialize each program and UCB will receive milestone and royalty payments from Wilex. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.